Cat. No.: DAB-0012388
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro255 of human PAPSS1 protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PAPSS1 |
| UniProt No. | O43252 |
| Gene ID | 9061 |
| Gene Description | PAPS Synthases 1 and 2 are bifunctional enzymes with both ATP sulfurylase and APS kinase activity. They mediate two reactions to generate 3'-phosphoadenosine-5'-phosphosulfate, a critical intermediate in the sulfate activation pathway. PAPS is the sulfate donor co-substrate for all sulfotransferase enzymes and is required to catalyze the sulfate conjugation of many endogenous and exogenous compounds. For example, PAPSS1 and PAPSS2 are responsible for catalyzing the sulfation of steroid hormones, which increases their water solubility and reduces their biological activity, suggesting modulation of PAPS synthases as a possible avenue for treatment of hormone-dependent cancers. Inhibition of PAPSS1 was also shown to increase the sensitivity of some cancer cell lines to DNA-damage agents both in vitro and in vivo, suggesting further potential utility for PAPS synthase inhibitors in cancer therapy. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
